TDSPharm Co

TDSPharm Co Diluted EPS

The Diluted Earnings per Share of TDSPharm Co (464280.KQ) as of Nov 20, 2026 is 808.27 KRW. In the previous year, Diluted Earnings per Share was 703.00 KRW — a change of 14.97% (higher).

Diluted EPS

808.27KRW

YoY

14.97%

Last updated:

Diluted Earnings per Share of TDSPharm Co is 2025 808.27 KRW. Diluted Earnings per Share of TDSPharm Co was 2024 703.00 KRW. It decreases by 14.97% higher compared to the previous year.

The TDSPharm Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2021
390.06 KRW
Jan 1, 2022
721.65 KRW
Jan 1, 2023
979.00 KRW
Jan 1, 2024
703.00 KRW
Jan 1, 2025
808.27 KRW
The TDSPharm Co Diluted EPS history
YEARDiluted EPSYoY
808.27KRW+14.97%
703.00KRW-28.19%
979.00KRW+35.66%
721.65KRW+85.01%
390.06KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Diluted Earnings per Share of TDSPharm Co is 808.27 KRW in 2025.

Diluted Earnings per Share of TDSPharm Co changed from 703.00 KRW to 808.27 KRW, representing a 14.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TDSPharm Co

All Key Metrics — TDSPharm Co